CARGO Therapeutics insider cashout: Options converted to cash and CVRs
Rhea-AI Filing Summary
John A. Orwin, a director of CARGO Therapeutics, Inc. (CRGX), reported changes in beneficial ownership tied to a completed merger on August 18-19, 2025. Pursuant to the Merger Agreement, a tender offer paid $4.379 per share in cash plus one non-transferable CVR per share and Merger Sub merged into the issuer, making the company a wholly owned subsidiary. Outstanding options became vested and exercisable; unexercised options were canceled and converted into cash equal to the excess of the cash amount over the option exercise price and one CVR per underlying share. Two specific options were disposed: a $1.09 strike for 15,865 shares and a $4.35 strike for 25,000 shares, both reported as exercised/disposed on 08/19/2025.
Positive
- Merger completed resulting in a definitive cash consideration of $4.379 per share plus one CVR per share.
- Outstanding options were accelerated and settled, allowing holders to receive cash for the intrinsic value of in-the-money options.
- Director's position was monetized through the tender offer and merger settlement for documented proceeds and CVRs.
Negative
- Options with exercise price equal to or greater than $4.379 were canceled for no consideration, potentially leaving some optionholders uncompensated.
- CVRs are non-transferable contractual contingent rights, which may limit immediate liquidity for part of the consideration received.
Insights
TL;DR: Merger closed; director's equity awards were cashed out and converted to CVRs, aligning insider outcomes with transaction terms.
The filing documents a completed acquisition where the issuer became a wholly owned subsidiary and vested options were settled per the Merger Agreement. From a governance perspective, this shows standard change-in-control mechanics: acceleration and cashout of options plus contingent consideration via CVRs. The treatment of in-the-money options (cash equal to difference between $4.379 and strike) preserves economic value for optionholders, while options with strike at or above the cash price were canceled for no consideration, as disclosed.
TL;DR: Insider reported disposal of two option grants tied to the deal; the $4.379 cash consideration plus CVRs determined final payouts.
Details show two option classes: 15,865 shares at $1.09 and 25,000 shares at $4.35, both reported disposed on 08/19/2025. The filing clarifies the formula for cash settlement and CVR issuance for canceled options, which informs valuation of proceeds received by insiders. This is a transaction-driven liquidity event rather than routine trading, and provides concrete per-share cash consideration useful for investor records.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 15,865 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
Footnotes (1)
- Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.
